Hematological Manifestations of Systemic Diseases

Introduction:

Systemic diseases cause manifestations in various organs and tissues. The involvement of blood and blood components is an integral part of the disease progression of any systemic disease. When the blood components are affected, several hematological changes occur in the body, producing different clinical features. The manifestations of systemic diseases can occur in any component, like the cellular component (red blood cells or platelets), the liquid portion (plasma), or other substances like plasma proteins.

What Are the Hematological Manifestations of Systemic Diseases?

1. Autoimmune Diseases: Autoimmune diseases like lupus, rheumatoid arthritis, or multiple sclerosis form an important component of systemic diseases with varied manifestations in several organs. These diseases are characterized by the body's aberrant and dysfunctional immune responses, leading to prolonged activation of inflammatory cascades and the resultant inflammation. As a result of persistent inflammation for a long period, the immune system destroys cells of the hematological system (autoimmune-mediated destruction). Thus, there are reduced parameters in the blood components like anemia (specifically autoimmune hemolytic anemia), leukopenia, or thrombocytopenia.

2. Infectious Diseases: Attacks by infectious agents are a very common cause of morbidity in humans. The hematological system is also affected.

• Viral infections like HIV (human immunodeficiency virus) are known to cause immune suppression in the body, thus leading to cytopenias, primarily CD4+ cell suppression.

• Hepatitis-causing viruses (Hepatitis B and C) can directly affect the bone marrow of infected individuals and significantly damage the hematopoietic stem cells. This finally leads to aplastic anemia in chronic stages, where the number of blood-forming cells goes below normal.

• Similarly, bacterial infections are known to affect the blood components. In advanced cases, bacterial infections cause toxic byproducts to spread throughout the body. This leads to widespread sepsis and disseminated intravascular coagulation (DIC). Gram-negative sepsis, in particular, is associated with endotoxin-induced activation of the coagulation cascade and widespread endothelial dysfunction.

• Toxin-producing bacteria like Staphylococcus aureus and Shigella can damage erythrocytes and thrombocytes. Hemolytic uremic syndrome and thrombocytopenic purpura are common diseases caused by such toxins.

• In parasitic infections like malaria (caused by Plasmodium species), there is lysis, dysregulation of erythrocytic activity, and spleen sequestration with the malaria-infected red blood cells. Also, parasitic infections, such as schistosomiasis and visceral leishmaniasis, can cause pancytopenia due to bone marrow infiltration and immune dysregulation.

• Candida and Aspergillus species, commonly implicated in invasive fungal infections, can produce tissue-destructive enzymes and trigger inflammatory responses that disrupt hemostasis (blood clotting mechanism) and endothelial integrity.

3. Metabolic Disorders: Abnormal and dysregulated chemical reactions in the body caused by a metabolic disorder can also cause havoc to the blood system. Metabolic disorders, such as hemoglobinopathies and disorders of iron metabolism, can profoundly affect the blood-forming process and lead to several hematological abnormalities. Sickle cell disease, for instance, results in chronic hemolysis (death of blood cells) and vaso-occlusive crises and increases the probability of acquiring new antigens and infections, culminating in anemia and thrombocytopenia. Thalassemias (impaired globin chain synthesis) can lead to ineffective erythropoiesis and hemolysis, resulting in anemia and splenomegaly. Disorders of iron metabolism, including iron deficiency anemia and hereditary hemochromatosis, can impact erythropoiesis and increase the likelihood of incidence of thrombosis.

4. Endocrine Disorders: Hematological abnormalities arising from endocrine disorders can arise primarily due to hormonal dysregulation or secondarily due to immune suppression and dysregulation of the bone marrow (hematopoietic system).

• The role of thyroxine hormone is paramount for optimal formation of blood cells in the body. Any deviation from the normal can lead to hematological abnormalities. Hypothyroidism is known to cause normocytic anemia and thrombocytopenia. Conversely, increased erythropoietin production and enhanced bone marrow activity in hyperthyroidism contribute to erythrocytosis, while platelet count elevation may be attributed to augmented megakaryopoiesis and platelet turnover. Also, hyperthyroidism-associated hypercoagulability increases the incidence of thrombotic events in hyperthyroid individuals.

• In cases of adrenal insufficiency, there is glucocorticoid deficiency, which tends to affect the hematopoietic process. Glucocorticoids are also responsible for maintaining normal immune activity in the body, and the absence of this in adrenal insufficiency can lead to aberrant immune activity and inflammation, which manifests as disease in the hematological system. In advanced cases, there is an adrenal crisis, and this leads to profound hypotension, shock, and disseminated intravascular coagulation (DIC).

• Hyperglycemic states seen in diabetes mellitus for a prolonged time directly impair the function of the kidneys (diabetic nephropathy). This results in deficit production of erythropoietin from the kidneys, thus resulting in chronic kidney anemia. Furthermore, diabetes-associated endothelial dysfunction and hypercoagulability also occur in individuals and lead to a thrombotic state. Diabetic ketoacidosis (a complication of prolonged diabetes) also causes hemodynamic instability and thrombosis.

How to Manage Hematological Abnormalities in Systemic Diseases?

Managing systemic diseases should be the first concern, as proper control and management can curb the severity of the associated hematological manifestations. This should be initiated by conducting a thorough assessment of the body and the stage of the systemic disease.

• Appropriate laboratory and radiological investigations should follow physical examination to understand the disease progression and plan treatment.

• In severe cases of hematological abnormalities, patients may require transfusion of either blood or blood components like packed red cells.

• Some people may also require the administration of growth factors to stimulate the production and differentiation of blood-forming cells.

• If the hematological abnormalities seen are due to immune dysregulation in the body, immune modulators like corticosteroids or immunosuppressants should be given.

• Antibiotics will be given to address the etiological factors related to infectious agents to dampen the hematological abnormalities associated with infections.

• Hematopoietic stem cell therapy and transplantation are potentially curative therapies for certain hematological manifestations associated with systemic diseases, such as severe aplastic anemia, autoimmune cytopenias, or hematological malignancies.

Any treatment to cure the hematological manifestations should be monitored regularly by checking the blood parameters frequently. This helps to point out any complications stemming from systemic diseases at an early stage.

Conclusion:

The hematological manifestations of systemic diseases serve as invaluable diagnostic clues, guiding clinicians toward the underlying pathophysiology and facilitating timely intervention. Understanding the diverse ways in which systemic diseases impact hematopoiesis and hemostasis is paramount for comprehensive patient care.